{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-202349","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.548311+00:00","generated_at":"2026-06-12T09:17:11.790193+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sensei Biotherapeutics Q2 2023 net loss $9.4M; SNS-101 Phase 1/2 enrolling 6 patients","bullets":["Cash, cash equivalents and marketable securities $78.8M at June 30, 2023, down from $107.1M at Dec 31, 2022; cash runway into H2 2025.","Net loss $9.4M vs $10.5M YoY; R&D expenses $4.8M (down from $6.4M) due to restructuring and lower manufacturing costs.","G&A expenses $5.4M included $1.56M non-recurring stockholder activism costs related to the 2023 annual meeting.","SNS-101 Phase 1/2 enrolled 6 patients across 3 cohorts; combination arm with Libtayo (cemiplimab) expected Q4 2023; PK/safety data by year-end 2023.","Robert Schreiber appointed Chair of Immuno-Oncology Advisory Board; SNS-102 and SNS-103 lead optimization completed, candidate selection expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-202349","json":"https://secwatch.observer/filing/0001193125-23-202349.json","markdown":"https://secwatch.observer/filing/0001193125-23-202349.md","text":"https://secwatch.observer/filing/0001193125-23-202349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523202349/0001193125-23-202349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523202349/d518119d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:17:11.790193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4090da2011088b42d5c08c4ddd48a0b5d09fd5f9","claim":"Sensei Biotherapeutics, Inc. reported second quarter ended June 30, 2023 results: net income Net loss was $9.4 million.","evidence_excerpt":"Net loss was $9.4 million for the quarter ended June 30, 2023, compared to $10.5 million for the quarter ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523202349/0001193125-23-202349-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $9.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}